muramidase has been researched along with Carcinoma--Bronchogenic* in 2 studies
2 other study(ies) available for muramidase and Carcinoma--Bronchogenic
| Article | Year |
|---|---|
Adenosine deaminase activity and lysozyme levels in bronchoalveolar lavage fluid in patients with pulmonary tuberculosis.
The estimations of adenosine deaminase (ADA) activity and lysozyme (LYS) levels in pleural fluid have been proved useful tools in the diagnosis of tuberculous pleural effusions. Little is known about their usefulness when estimated in bronchoalveolar lavage fluid (BALF).. To evaluate whether both ADA activity and LYS levels in BALF could be employed in the diagnosis of pulmonary tuberculosis, and especially in active but acid fast bacilli (AFB) smear negative cases.. ADA activity and LYS levels were determined in BALF and serum obtained on the same day in 28 patients with tuberculosis, 21 with interstitial lung diseases, 14 with lung cancer and 13 with infectious diseases.. Patients with pulmonary tuberculosis had significantly higher ADA activity in BALF than patients with non-tuberculous lung diseases (P < 0.001). High BALF ADA activity in pulmonary tuberculosis patients suggests increased local production. In contrast, in this group of patients BALF LYS levels were not significantly higher than in the other groups of patients, but were in the group with interstitial lung diseases.. BALF ADA activity seems to be a useful tool in the differentiation of tuberculosis from other lung diseases. Its estimation can be restricted to the detection of cases with AFB negative smears. Topics: Adenosine Deaminase; Bronchoalveolar Lavage Fluid; Carcinoma, Bronchogenic; Case-Control Studies; Clinical Enzyme Tests; Diagnosis, Differential; Female; Humans; Lung Diseases; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Muramidase; Tuberculosis, Pulmonary | 1998 |
[Immunoglobulin and lysozyme levels in bronchoalveolar lavage fluid from patients with acute pneumonia in acute leukemia and bronchogenic carcinoma of the lung].
The study of immunoglobulins and lysozyme in acute pneumonia patients suffering from acute leukemia and bronchogenic cancer of the lungs elicited impairment of local specific and nonspecific body defences. This fact should be taken into consideration when planning immunotherapy in combined treatment of relevant patients. Topics: Bronchoalveolar Lavage Fluid; Carcinoma, Bronchogenic; Humans; Immunoglobulins; Lung Neoplasms; Muramidase; Pneumonia; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1990 |